1)Rose EA, et al:Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 345:1435-1443, 2001
2)Slaughter MS, et al:Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 361:2241-2251, 2009
3)Strueber M, et al:Successful use of the heartware hvad rotary blood pump for biventricular support. J Thorac Cardiovasc Surg 140:936-937, 2010
4)Levy WC, et al:The seattle heart failure model:Prediction of survival in heart failure. Circulation 113:1424-1433, 2006
5)Nakayama M, et al:Validation of mortality risk stratification models for cardiovascular disease. Am J Cardiol 108:391-396, 2011
6)Miller LW:Listing criteria for cardiac transplantation:Results of an american society of transplant physicians-national institutes of health conference. Transplantation 66:947-951, 1998
7)Stehlik J, et al:The registry of the international society for heart and lung transplantation:Twenty-seventh official adult heart transplant report―2010. J Heart Lung Transplant 29:1089-1103, 2010
8)Davis SF, et al:Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation 93:457-462, 1996
9)Haddad F, et al:Changing trends in infectious disease in heart transplantation. J Heart Lung Transplant 29:306-315, 2010
10)Gao SZ, et al:Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients:30-year experience at stanford university. J Heart Lung Transplant 22:505-514, 2003
11)Schubert S, et al:Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients. Pediatr Transplant 13:54-62, 2009
12)Takahashi K, et al:Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-872, 2007
13)Tohyama S, et al:Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 12:127-137, 2013
14)Kawamura M, et al:Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation 126:S29-37, 2012
15)Hattori F, et al:Nongenetic method for purifying stem cell-derived cardiomyocytes. Nat Methods 7:61-66, 2010